Vivodyne raises $40M for human tissue drug testing
Why it matters: Vivodyne says demand is "surging" from pharma clients following the FDA's announced plans to "phase out" animal testing requirements in drug development.
Follow the money: New investors include Lingotto Investment Management, Helena Capital and Fortius Ventures.
Existing investors Kairos Ventures, CS Ventures, Bison Ventures and MBX Capital also participated.
Vivodyne has raised about $78 million to date, after a $38 million seed round in 2023.
CEO Andrei Georgescu wouldn't disclose Vivodyne's valuation but said it grew significantly with the Series A.
How it works: Vivodyne is using automated robotic platforms and AI to grow thousands of lab-grown, fully functional human tissues and produce data to discover and develop drugs.
The pre-clinical technology is designed to be used in lieu of animal testing, and Vivodyne says its platform can improve the success rate in human trials.
The platform can produce human bone marrow, lymph nodes, liver and other organs, and model diseases, including cancer, fibrosis, autoimmunity and infections.
Zoom in: Top pharma companies are already testing drugs and therapies using Vivodyne's approach.
"We are a partnerships company that spans the entire breadth of preclinical development," Georgescu says.
The company, which employs about 40 people, also has some of its own drug programs but Georgescu declined to share specific disease targets.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
a few seconds ago
- Medscape
Preterm Birth Predicts Adult Health Problems
Adults born preterm were significantly more likely to have cardiometabolic risk factors and internalized mental health issues than full-term peers, according to an ongoing preterm birth cohort study in the US. 'This study addresses a significant gap in understanding the long-term health effects of preterm birth in the US,' said lead author Amy D'Agata, PhD, of the College of Nursing, The University of Rhode Island, Kingston, Rhode Island, in an interview. Although the annual preterm birth rate in the US has held at a relatively stable 10%-12% for decades, since the 1970s, more preterm infants are surviving because of advances in neonatal intensive care, D'Agata said. Millions of individuals born preterm are aging into adulthood, but few data are available on their long-term health outcomes, she noted. In the new study, published in JAMA Network Open , D'Agata and colleagues reviewed data from a cohort of individuals who received level III neonatal intensive care at a single center between 1985 and 1989. The study population included 158 preterm-born and 55 full-term born adult control individuals. Preterm was defined as weighing under 1850 g at birth with various neonatal diagnoses; critically ill infants and those with major congenital abnormalities were excluded. The mean age across the groups was 35 years; 50% were women. The researchers used latent growth curve models to show changes over time. Overall, the preterm individuals who had higher medical risk in early life were significantly more likely to have a range of health problems at 35 years of age, notably, higher triglycerides than control individuals (beta value, 53.97; P = .03). Measures of systolic blood pressure and central adiposity also were significantly higher in the preterm birth group (beta values of 7.15 and 0.22, respectively), whereas bone density and high-density lipoprotein cholesterol were lower (beta values of -1.14 and -13.07, respectively). In addition, internalizing mental health problems were significantly more common in the preterm cohort than in the control individuals (beta value, 0.85; P = .01) but no difference in externalizing mental health problems was noted between the groups. The researchers also reviewed the impact of social protection and childhood socioeconomic status and found no association between these and physical or psychological health risks in adults born preterm. The Long View of Preterm Birth The population of adults born preterm remains largely invisible to the US healthcare system and its clinicians, highlighting critical issues of health equity and quality of care, D'Agata told Medscape Medical News . 'Much of the existing research in this area has focused on international, homogeneous populations, creating a need for rigorous, US-based longitudinal data to guide healthcare policy and clinical practice,' she added. 'These findings generally confirmed what has been observed internationally, that there is a link between higher early life medical risk and increased likelihood of mental health issues, elevated systolic blood pressure, unfavorable cholesterol and triglyceride levels, body fat distribution, and lower bone density among adults born preterm, and it was notable to see these clear and consistent associations replicated in a US cohort using a prospective, longitudinal design,' said D'Agata. The study findings emphasized the need to inquire about birth history in adult care settings and suggest that those born preterm and their families must be their own health advocates, if necessary, said D'Agata. 'Even if a patient isn't asked about their birth history, they should share it,' she noted. Clinicians work hard to provide the best care, but it takes time for evidence-based research to inform clinical practice, she said. 'Although our birth cohort is small and comes from a single geographic region, the results generally align with international findings,' D'Agata told Medscape Medical News . However, future studies should include more racially and ethnically diverse cohorts from multiple clinical settings, she said. Research is needed not only to examine which subgroups of preterm individuals are most at risk but also to differentiate between those with varying degrees of early life complications, she added. Long Follow-Up Strengthens Findings The 35-year duration of the preterm birth cohort study was impressive and valuable, said Tim Joos, MD, a clinician with a combination internal medicine/pediatrics practice at Neighborcare Health in Seattle. 'We don't often have the long game in mind, in healthcare as well as in other parts of our society,' said Joos, who was not involved in the study. 'We don't tend to follow pediatric conditions into adulthood,' he noted. The current study findings demonstrated a long-term psychological and physical impact of prematurity on adult health that was humbling, Joos told Medscape Medical News . Looking ahead, the results highlight not only the need to continue to prevent preterm birth but also to the importance of asking older patients about preterm birth as part of their health history, he said.
Business Wire
an hour ago
- Business Wire
Wikifarmer Launches UK Operations to Transform Olive Oil Sourcing for British Businesses
LONDON--(BUSINESS WIRE)--Wikifarmer, the Athens and Seville-based online agricultural marketplace, is launching UK operations to connect British businesses directly with Mediterranean olive oil producers. With Spanish olive oil prices down 53% year-over-year to €3.55/kg¹, this expansion targets Britain's £320 million olive oil market², projected to reach $1.55 billion by 2030⁶. "Our platform offers free access to quality European producers, with no hidden charges" Share Direct Access. Lower Costs. Greater Transparency. Wikifarmer's platform connects businesses directly with verified Mediterranean producers, eliminating intermediaries to provide transparent pricing, reliable logistics, and flexible credit terms with no subscription fees. The free-to-use model has connected over 7,000 buyers with 15,000 suppliers, facilitating millions in direct trade transactions. "The UK represents a massive opportunity to revolutionize how British businesses source Mediterranean olive oil," says Wikifarmer Co-Founder and CEO, Ilias Sousis. "We offer buyers direct access to quality European producers with the reliability and support they demand." Meeting UK Market Needs British businesses faced olive oil import price increases of 44% in 2024 while dealing with supply chain uncertainties. "Our platform offers free access to quality European producers, with no hidden charges," says Sam Frearson, UK Sales Manager. The UK's £128 billion food and agriculture sector¹¹ relies on traditional supply chains with multiple intermediaries, driving up costs and reducing transparency. Spain supplies 62% of UK olive oil imports, Italy 26%⁴, but most trade passes through costly middlemen. UK olive oil import values rose 31.7% to £333.2 million in 2023⁸, with olive oil comprising 87.1% of Britain's olive market⁷. Recent recovery in global production and a 13.9% drop in EU prices signal market stabilization¹⁰, making now ideal for direct sourcing. Expansion Plans The UK team will focus on onboarding buyers in wholesale, hospitality, retail, and food processing. This expansion advances Wikifarmer's vision to create a digital marketplace connecting farmers directly with buyers, eliminating intermediaries for fair, transparent trade. The company plans further European expansion throughout 2025. About Wikifarmer Wikifarmer ( combines the world's largest agricultural knowledge library with an online B2B marketplace. With over 20,000 direct transactions, Wikifarmer helps businesses reduce costs and supports farmers' profitability.
an hour ago
Sarepta will resume gene therapy shipments after FDA review of recent patient death
WASHINGTON -- Shares of beleaguered drugmaker Sarepta Therapeutics jumped in afterhours trading Monday after the company said it would resume shipping its gene therapy for some patients, following a brief pause requested by regulators. The Food and Drug Administration said it recommended lifting the hold for young patients with Duchenne's muscular dystrophy who are still able to walk. Regulators had requested the pause after the deaths of two older teenagers who were taking the therapy. The FDA also said in a statement it determined that a recently reported death of an 8-year-old boy was unrelated to the therapy. Company shares surged more than 16% after the announcement to $13.86 in afterhours trading. The jump is the latest in a series of drastic stock movements triggered by changing fortunes for the company's best-selling product. Elevidys is the first gene therapy approved in the U.S. for Duchenne's muscular dystrophy, the fatal muscle-wasting disease that affects boys and young men, resulting in early death. It received accelerated approval in 2023 for a narrow range of young patients and was expanded last year for use in older patients, including those who can no longer walk. The FDA decision Monday 'significantly improves Elevidys' sales outlook in the near-term,' Jefferies analyst Andrew Tsai told investors, in a note after the announcement. 'The street will feel relieved about the situation, suggesting meaningful stock upside potential.' Sarepta's therapy has been under scrutiny from regulators after two teenage boys died earlier this year from acute liver injury, a known side effect of the treatment. The FDA then requested a pause in shipments of the drug after the death of a third patient taking a different Sarepta therapy. FDA officials have suggested the company will need to provide new study data on safety to resume Elevidys' use in older patients. 'The FDA will continue to work with the sponsor regarding non-ambulatory patients, which remains subject to a voluntary hold, following two deaths,' FDA said in its statement. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
